This bill, known as the Dismemberment Abortion Ban Act of 2026, prohibits physicians from performing abortions that involve dismembering an unborn child piece by piece or crushing it with instruments, with the specific intent of causing the child's death. The law defines an "unborn child" as a human organism from fertilization until birth and allows for exceptions only when the procedure is necessary to save the life of the mother due to a physical disorder, illness, or injury. While it bans this specific method, the bill explicitly states that other abortion methods remain legal for reasons such as rape or incest, and it removes the previous federal ban on partial-birth abortions from the legal code. Violators face criminal penalties including fines and up to two years in prison, while women undergoing these procedures are immune from prosecution. Additionally, the bill creates a civil remedy allowing women or parents of minors to sue physicians for money damages, psychological injury, and punitive damages if the ban is violated.
This Senate resolution commemorates the fourth anniversary of the 2022 Supreme Court decision in Dobbs v. Jackson Women's Health Organization, which overturned the previous federal right to abortion. The document expresses the Senate's support for state authority to regulate abortion and acknowledges the work of pregnancy centers that assist expectant mothers. It formally declares the Senate's commitment to protecting unborn life and supporting families, while noting the ongoing policy challenges related to abortion access. As a symbolic measure, the bill does not create new laws or alter existing regulations but serves to record the Senate's stance on the issue.
The Nitrous Oxide Safety Act of 2026 would classify consumer products containing nitrous oxide as banned hazardous items under federal law, except for specific exceptions. The bill prohibits the sale of nitrous oxide products for recreational use while allowing continued sales for medical and dental treatments, food production in commercial kitchens, research and development activities, and food propellant applications. This legislation directly affects manufacturers, retailers, and consumers by restricting access to nitrous oxide in consumer products after 180 days from enactment. The law defines nitrous oxide as the gas known as laughing gas or whippits and specifies which entities and activities are exempt from the ban.
This bill would remove the federal approval for the drug mifepristone, which is used in combination with other medications to end pregnancies, and would make it illegal to distribute the drug for that purpose. It also creates a new federal lawsuit option allowing individuals to sue drug manufacturers for physical or mental harm they claim resulted from using mifepristone. The law would take effect 14 days after passing, with the new lawsuit provision becoming active 90 days after enactment.
This bill declares that the constitutional right to life applies to all human beings from the moment of conception, including fertilization. It states that Congress intends to implement this right under its powers in Article I and the 14th Amendment. The bill explicitly clarifies it does not require prosecuting women for pregnancy outcomes, ban in vitro fertilization, or restrict birth control methods. It defines "human person" to include individuals at all life stages starting at conception.
HR 682, the Heartbeat Protection Act of 2025, prohibits physicians from performing abortions without first checking for a detectable fetal heartbeat according to standard medical practice and informing the patient of the results. It directly affects physicians and clinics performing abortions, requiring them to document heartbeat checks and comply with strict exceptions for life-threatening conditions, rape (with 48-hour documentation of counseling/treatment), or incest involving minors (with proof of prior report to authorities). Violations could result in fines or up to five years in prison, though the bill explicitly states it does not create or recognize a right to abortion. The law adds detailed documentation requirements for exceptions and mandates retention of medical records per federal health privacy rules.
Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This act permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Under the act, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term). Additionally, the act establishes a new, alternative registration process for certain schedule I research. The act also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration. Finally, the act expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray , a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.
HR 1303, the Protecting America’s Seniors’ Access to Care Act, would block the federal government from enforcing a 2024 rule requiring nursing homes to meet minimum staffing standards and mandating Medicaid programs to report payment transparency details. This bill directly affects long-term care facilities and Medicaid programs by preventing the implementation of these specific requirements. The legislation prohibits the Secretary of Health and Human Services from carrying out the rule published on May 10, 2024, which was designed to improve care quality and accountability in senior healthcare. It stops the rule from taking effect without creating new policies or regulations.
HR 7 prohibits federal funds from being used for abortions or health insurance plans covering abortion, with exceptions for pregnancies resulting from rape, incest, or when a woman's life is endangered. It blocks federal premium tax credits under the Affordable Care Act for health plans covering abortion (except in specified cases) and requires clear disclosure of abortion coverage and related surcharges in plan materials. The bill allows individuals or employers to purchase separate abortion coverage using non-federal funds, such as out-of-pocket payments, without affecting federal subsidies. It directly affects federal health programs, ACA marketplace plans, and health insurance issuers offering coverage that includes abortion services.
This bill prohibits federal funds from being used to cover gender transition procedures for individuals under 18, including puberty blockers, hormone therapies (at higher-than-normal doses), and surgeries like hysterectomies or mastectomies. It defines "sex" biologically as male or female and exempts certain medical treatments, such as puberty suppression for precocious puberty or care for genetic disorders of sex development. The policy directly affects minors receiving federally funded healthcare (e.g., Medicaid), restricting coverage for most gender-affirming care. Key mechanisms include funding restrictions and specific medical exceptions, though it does not ban private insurance or out-of-pocket payments.
